secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000010795-23-000072
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q3 revenue $4.88B up 5.1%, adjusted EPS $2.96 up 11.3%, raises FY revenue guidance
--------------------------------------------------------------------------------

- Revenue of $4.88B, up 5.1% as reported, 6.3% currency-neutral; base revenue growth 6.7% as reported.
- GAAP diluted EPS $1.36; adjusted diluted EPS $2.96 vs $2.66 YoY, up 11.3%.
- Raised full-year base organic revenue growth guidance; maintained full-year adjusted EPS guidance.
- Received FDA 510(k) clearance for updated BD Alaris Infusion System, a key BD 2025 milestone.
- Completed sale of Surgical Instrumentation platform to STERIS for $540M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079523000072/0000010795-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079523000072/bdx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000010795-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer